{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Non-Hodgkin+Lymphoma&page=21", "query": { "condition": "T-cell Non-Hodgkin Lymphoma", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 1253, "total_pages": 126, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Non-Hodgkin+Lymphoma&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Non-Hodgkin+Lymphoma&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T09:34:58.654Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00070018", "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Yttrium-90 ibritumomab tiuxetan", "type": "BIOLOGICAL" }, { "name": "Indium-111 ibritumomab tiuxetan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2004-02", "completion_date": "2015-01-08", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 48, "location_summary": "Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Burbank", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070018" }, { "nct_id": "NCT00798096", "title": "Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Cell Lymphoma" ], "interventions": [ { "name": "Fostamatinib Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 8, "location_summary": "San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798096" }, { "nct_id": "NCT05665062", "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL/SLL", "NHL", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Large B-cell Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "SYNCAR-001", "type": "DRUG" }, { "name": "STK-009", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-04-23", "completion_date": "2041-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 4, "location_summary": "Duarte, California • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05665062" }, { "nct_id": "NCT00725062", "title": "Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CD4+CD25+ regulatory T cells", "type": "BIOLOGICAL" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2008-06", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725062" }, { "nct_id": "NCT04629729", "title": "FT819 in Subjects With B-cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell", "Chronic Lymphocytic Leukemia", "Precursor B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "FT819", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-07-12", "completion_date": "2039-09-30", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629729" }, { "nct_id": "NCT04975698", "title": "HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Associated Lymphoma" ], "interventions": [ { "name": "HST-NEETs", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Catherine Bollard", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 12, "start_date": "2021-10-25", "completion_date": "2026-01-05", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 11, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975698" }, { "nct_id": "NCT00398372", "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphomas: Non-Hodgkin", "Lymphomas: Non-Hodgkin Cutaneous Lymphoma", "Lymphomas: Non-Hodgkin Diffuse Large B-Cell", "Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell", "Lymphomas: Non-Hodgkin Mantle Cell", "Lymphomas: Non-Hodgkin Marginal Zone", "Lymphomas: Non-Hodgkin Peripheral T-Cell", "Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Epratuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2000-11", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2011-06-02", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00398372" }, { "nct_id": "NCT01564277", "title": "Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "de Novo Myelodysplastic Syndromes", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "rasburicase", "type": "DRUG" }, { "name": "allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2011-09-29", "completion_date": "2016-05-28", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01564277" }, { "nct_id": "NCT05757700", "title": "Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Large B-cell Lymphoma", "DLBCL, Nos Genetic Subtypes", "High-grade B Cell Lymphoma", "Mediastinal Large B-cell Lymphoma" ], "interventions": [ { "name": "19(T2)28z1xx TRAC T cell", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-02-23", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757700" }, { "nct_id": "NCT01644253", "title": "Phase 1b Safety and Efficacy Study of TRU-016", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "20 mg/kg TRU-016 + Rituximab", "type": "BIOLOGICAL" }, { "name": "10 mg/kg TRU-016 + Rituximab", "type": "BIOLOGICAL" }, { "name": "TRU-016 20 mg/kg + Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "TRU-016 6-20 mg/kg + idelalisib + rituximab", "type": "BIOLOGICAL" }, { "name": "TRU-016 10-20 mg/kg + ibrutinib", "type": "BIOLOGICAL" }, { "name": "TRU-016 10-20 mg/kg + bendamustine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aptevo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2012-09", "completion_date": "2021-04-21", "has_results": false, "last_update_posted_date": "2021-05-20", "last_synced_at": "2026-10-16T09:34:58.654Z", "location_count": 8, "location_summary": "Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644253" } ] }